CS1 chimeric antigen receptor T-cell

CS1 chimeric antigen receptor T-cell therapy is an autologous cell therapy targeting the CS1 (also known as SLAMF7 or CD319) antigen. CS1 is a cell surface glycoprotein that is highly and consistently expressed on malignant plasma cells in multiple myeloma, while its expression on normal tissues is restricted to natural killer cells, some subsets of T cells, and mature B cells. The therapy involves the genetic modification of a patient's own T cells to express a chimeric antigen receptor (CAR) specific for CS1, enabling the T cells to recognize and eliminate CS1-expressing tumor cells. This specific clinical program, led by Tongji Hospital of Huazhong University of Science and Technology, is investigating the safety and efficacy of CS1 CAR-T cells in patients with relapsed or refractory CS1-positive hematological malignancies, including multiple myeloma, systemic light-chain amyloidosis, and POEMS syndrome.

Other names

CS1 CAR-TCS-1 CAR-TCS 1 CAR-TSLAMF7 chimeric antigen receptor T-cellSLAMF-7 chimeric antigen receptor T-cellSLAMF 7 chimeric antigen receptor T-cellCS1-targeted CAR-T cellsCS-1-targeted CAR-T cellsCS 1-targeted CAR-T cells